The serine/threonine kinase AKT is generally accepted as a promising anticancer therapeutic target.However,the relief of feedback inhibition and enhancement
SL-01,an oral gemcitabine derivative,was synthesized by introducing the moiety of 3-(dodecyloxycarbonyl) pyrazine-2-carbonyl at the N4-position on the cytid
Neratinib (HIK-272),an irreversible inhibitor of EGFR and Her-2,is in phase Ⅲ clinical trials for patients with Her-2-positive locally advanced or metastat